Abstract
An inevitable consequence of humans living in the Aluminium Age is the presence of aluminium in the brain. This non-essential, neurotoxic metal gains entry to the brain throughout all stages of human development, from the foetus through to old age. Human exposure to myriad forms of this ubiquitous and omnipresent metal makes its presence in the brain inevitable, while the structure and physiology of the brain makes it particularly susceptible to the accumulation of aluminium with age. In spite of aluminium’s complete lack of biological essentiality, it actually participates avidly in brain biochemistry and substitutes for essential metals in critical biochemical processes. The degree to which such substitutions are disruptive and are manifested as biological effects will depend upon the biological availability of aluminium in any particular physical or chemical compartment, and will under all circumstances be exerting an energy load on the brain. In short, the brain must expend energy in its ‘unconscious’ response to an exposure to biologically available aluminium. There are many examples where ‘biological effect’ has resulted in aluminium-induced neurotoxicity and most potently in conditions that have resulted in an aluminium-associated encephalopathy. However, since aluminium is non-essential and not required by the brain, its biological availability will only rarely achieve such levels of acuity, and it is more pertinent to consider and investigate the brain’s response to much lower though sustained levels of biologically reactive aluminium. This is the level of exposure that defines the putative role of aluminium in chronic neurodegenerative disease and, though thoroughly investigated in numerous animal models, the chronic toxicity of aluminium has yet to be addressed experimentally in humans. A feasible test of the ‘aluminium hypothesis’, whereby aluminium in the human brain is implicated in chronic neurodegenerative disease, would be to reduce the brain’s aluminium load to the lowest possible level by non-invasive means. The simplest way that this aim can be fulfilled in a significant and relevant population is by facilitating the urinary excretion of aluminium through the regular drinking of a silicic acid-rich mineral water over an extended time period. This will lower the body and brain burden of aluminium, and by doing so will test whether brain aluminium contributes significantly to chronic neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Graphical Abstract
The co-localisation of aluminium (purple) and amyloid (red) in human brain tissue

This is a preview of subscription content, access via your institution.


References
- 1.
Exley C (2009) Trends Biochem Sci 34:589
- 2.
Crapper DR, Krisnan SS, Dalton AJ (1973) Science 180:511
- 3.
Legendre GR, Alfrey AC (1976) Clin Chem 22:53
- 4.
Freundlich M, Zilleruelo G, Abitbol C, Strauss J, Faugere M-C, Malluche HH (1985) Lancet 7:527
- 5.
Bishop NJ, Robinson MJ, Lendon M, Hewitt CD, Day JP, O’Hara M (1989) Arch Dis Childhood 64:1316
- 6.
Bozynski MEA, Sedman AB, Naglie RA, Wright EJ (1989) J Parenteral Enteral Nutr 13:428
- 7.
Van Ginkel MF, van der Voet GB, de Wolff FA (1990) Clin Chem 36:658
- 8.
Yasui M, Yase Y, Ota K, Mukoyama M, Adachi K (1991) NeuroToxicol 12:277
- 9.
Lukiw WJ, Krishnan B, Wong L, Kruck PA, Bergeron C, Crapper McLachlan DR (1992) Neurobiol Aging 13:115
- 10.
Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Ann Neurol 31:286
- 11.
Xu N, Majidi V, Markesbery WR, Ehmann WD (1992) NeuroToxicol 13:735
- 12.
Candy JM, McArthur FK, Oakley AE, Taylor GA, Chen CPL-H, Mountfort SA, Thompson JE, Chalker PR, Bishop HE, Beyreuther K, Perry G, Ward MK, Martyn CN, Edwardson JA (1992) J Neurolog Sci 107:210
- 13.
Lovell MA, Ehmann WD, Markesbery WR (1993) Ann Neurol 33:36
- 14.
Moreno A, Dominguez C, Ballbriga A (1994) Acta Paediatr 83:25
- 15.
Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM (1994) Lancet 343:993
- 16.
Bush VJ, Moyer TP, Batts KP, Parisi JE (1995) Clin Chem 41:284
- 17.
Hantson P, Mahieu P, Gersdorff M, Sindic C, Lauwerys R (1995) Clin Toxicol 33:645
- 18.
Andrási E, Farkas E, Scheibler H, Réffy A, Bezúr L (1995) Arch Gerontol Geriatr 21:89
- 19.
Galassi G, Cappelli G, Crisi G, Botticelli AR, Lursvarghi E, Winkelmann MD, Lovell MA, Ehmann WD, Markesbery WR (1995) Trace Elem Electrolytes 12:68
- 20.
Reusche E, Koch V, Friedrich H-J, Nünninghoff D, Stein P, Rob P-M (1996) Clin Neuropathol 15:342
- 21.
Deibel MA, Ehmann WD, Candy JM, Ince PG, Shaw PJ, Markesbery WR (1997) Trace Elem Electrolytes 14:51
- 22.
Beauchemin D, Kisilevsky R (1998) Anal Chem 70:1026
- 23.
Roider G, Drasch G (1999) Trace Elem Electrolytes 16:77
- 24.
Reusche E, Pilz P, Oberascher G, Lindner B, Egensperger R, Gloeckner K, Trinka E, Iglseder B (2001) Hum Pathol 32:1136
- 25.
Meshitsuka S, Koeda T, Hara T, Takeshita K (2001) Dev Med Child Neurol 43:286
- 26.
De Wolff FA, Berend K, van der Voet GB (2002) Forensic Sci Int 128:41
- 27.
Zatta P, Zambenedetti P, Reusche E, Stellmacher F, Cester A, Albanese P, Meneghel G, Nordio M (2004) Nephrol Dial Transplant 19:2929
- 28.
Andrási E, Páli N, Molnár Z, Kösel S (2005) J Alzheimers Dis 7:273
- 29.
Exley C, Esiri MM (2006) J Neurol Neurosurg Psychiatry 77:877
- 30.
Perl DP, Brody AR (1980) Science 208:297
- 31.
Walton JR (2006) Neurotoxicol 27:385
- 32.
Yumoto S, Horino Y, Mokuno Y, Kakimi S, Fujii K (1996) Nucl Instr Meth Phys Res B 109/110:362
- 33.
Solomon B, Koppel R, Jossiphov J (2001) Brain Res Bull 55:253
- 34.
Bouras C, Giannakopoulos P, Good PF, Hsu A, Hof PR, Perl DP (1997) Eur Neurol 38:53
- 35.
Hirsch EC, Brandel J-P, Galle P, Javoy-Agid F, Agid Y (1991) J Neurochem 56:446
- 36.
Tokutake S, Oyanagi S (1995) Gerontol 52:131
- 37.
Yumoto S, Kakimi S, Ohsaki A, Ishikawa A (2009) J Inorg Biochem 103:1579
- 38.
Bouras C, Giannakopoulos P, Good PF, Hsu A, Hof PR, Perl DP (1996) Acta Neuropathol 92:351
- 39.
Aranyosiova M, Kopani M, Rychly B, Jakubovsky J, Velic D (2008) App Surf Sci 255:1123
- 40.
Itoh M, Suzuki Y, Sugai K, Ozuka N, Ohsawa M, Otsuki T, Goto Y (2008) J Child Neurol 23:938
- 41.
Reusche E, Seydel U (1993) Acta Neuropathol 86:249
- 42.
Shirabe T, Irie K, Uchida M (2002) Neuropathol 22:206
- 43.
Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S, Polwart A, Hawkins C (2006) Multiple Sclerosis 12:533
- 44.
Exley C, Price NC, Kelly SM, Birchall JD (1993) FEBS Lett 324:293
- 45.
Scott CW, Fieles A, Sygowski LA, Caputo CB (1993) Brain Res 628:77
- 46.
Uversky VN, Li J, Fink AL (2001) J Biol Chem 276:44284
- 47.
Walton JR (2009) Neurotoxicol 30:11059
- 48.
Exley C, Korchazhkina O, Job D, Strekopytov S, Polwart A, Crome P (2006) J Alzheimers Dis 10:17
- 49.
Van Landeghem GF, Dhaese PC, Lamberts LV, Barata JD, DeBroe ME (1997) Nephrol Dial Transplant 12:1692
- 50.
Eckstein JA, Ammerman GM, Reveles JM, Ackermann BL (2008) J Neurosci Meth 171:190
- 51.
Czarnecka J, Cieslak J, Michal K (2005) J Chromatography B 822:85
- 52.
Perl DP, Good PF (1987) Lancet 1:1028
- 53.
Kumar V, Gill KD (2009) Arch Toxicol 83:965
- 54.
Banks WA, Kastin AJ (1983) Lancet 2:1227
- 55.
Beardmore J, Exley C (2009) J Inorg Biochem 103:205
- 56.
Exley C (2004) Free Rad Biol Med 36:380
- 57.
Khan A, Dobson J, Exley C (2006) Free Rad Biol Med 40:557
- 58.
Exley C (1999) J Inorg Biochem 76:133
- 59.
Abbracchio MP, Burnstock G, Verkhratsky A, Zimmerman H (2009) Trends Neurosci 32:19
- 60.
Lukiw WJ (2010) J Inorg Biochem 104:1010
- 61.
Karlik SJ, Eichhorn GL, McLachlan DRC (1980) Neurotoxicol 1:83
- 62.
Chen L, Yokel RA, Hennig B, Toborek M (2008) J Neuroimmune Pharmacol 3:286
- 63.
Exley C, Siesjö P, Eriksson H (2010) Trends Immunol 31:103
- 64.
Becaria A, Lahiri DK, Bondy SC, Chen DM, Hamadeh A, Li H, Taylor R, Campbell A (2006) J Neuroimmunol 176:16
- 65.
Perl DP, Fogarty U, Harpaz N, Sachar DB (2004) Inflamm Bowel Dis 10:881
- 66.
Campbell A, Bondy SC (2000) Cell Mol Biol 46:721
- 67.
Exley C (2003) J Inorg Biochem 97:1
- 68.
Exley C (2009) Aluminium and medicine. In: Merce ALR, Felcman J, Recio MAL (eds) Molecular and supramolecular bioinorganic chemistry: applications in medical sciences. Nova Science Pub Inc, New York, p 45
- 69.
Exley C, House E, Collingwood JF, Davidson M, Cannon D, Donald AM (2010) J Alzheimers Dis 20:1159
Acknowledgments
Andrew Lawrence (Keele, KUDIS) is thanked for help in preparing Fig. 2. G Forster and Professor PG Ince (Royal Hallamshire Hospital, Sheffield) are thanked for help in providing brain tissues from MRC CFAS.
Author information
Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Exley, C., House, E.R. Aluminium in the human brain. Monatsh Chem 142, 357–363 (2011). https://doi.org/10.1007/s00706-010-0417-y
Received:
Accepted:
Published:
Issue Date:
Keywords
- Metal
- Neurodegenerative disease
- Neuropathology
- Neurotoxicity
- Alzheimer’s disease
- Parkinson’s disease